Recent Reports

A draft evidence report assessing the comparative clinical effectiveness and value of crisaborole (Eucrisa™, Pfizer, Inc.) and dupilumab (Dupixent®, Sanofi and Regeneron, Inc.) for treatment of atopic dermatitis. This report is open to public comment for four weeks. More information on submitting public comment is available here.

View More on this Topic

ICER’s revised Evidence Report of treatments for rheumatoid arthritis. A draft version of this report was open to public comment for four weeks. This updated report will serve as the basis for a March 24, 2017 meeting of the New England CEPAC.

View More on this Topic

ICER’s final report on disease-modifying therapies for multiple sclerosis. The final report includes a summary of a February 2017 meeting of the California Technology Assessment Forum.

View More on this Topic

ICER’s final report reviewing the comparative clinical effectiveness and value of targeted immunomodulators for treatment of moderate to severe plaque psoriasis. The report includes a summary of voting and policy implications from a November 2016 meeting of the New England CEPAC in Boston, MA.

View More on this Topic

Materials

CTAF

Chronic Low Back and Neck Pain: Open Input Period

New England CEPAC

Rheumatoid Arthritis: Revised Voting Questions

New England CEPAC

Rheumatoid Arthritis: ICER’s Response to Comments

Midwest CEPAC

Ovarian Cancer: Stakeholder List

CTAF

Multiple Sclerosis: Report-at-a-Glance

ICER

White Paper: Gene Therapy

New England CEPAC

Psoriasis: Model Analysis Plan

Midwest CEPAC

Atopic Dermatitis: Model Analysis Plan

Midwest CEPAC

Atopic Dermatitis: Research Protocol

CTAF

Multiple Sclerosis: Evidence Presentation

Midwest CEPAC

Ovarian Cancer: Draft Scoping Document

CTAF

Multiple Sclerosis: ICER’s Response to Public Comments